Saxenda Approved for Weight Management New Phase 3a data indicates that overweight or obese adults with comorbidities had greater improvements in weight loss, fasting plasma glucose (FPG), systolic ...

Novo Nordisk A/S NVO announced the presentation of new data from the phase IIIa SCALE Obesity and Prediabetes study on Saxenda at The Endocrine Society’s Annual Meeting. According to the new data, ...

The randomized, double-blind, placebo-controlled, parallel-group study (N=9340) evaluated the time from randomization to first occurrence of major adverse CV events (MACE) (non-fatal heart attack, non ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

Please provide your email address to receive an email when new articles are posted on . Saxenda, approved to treat obesity and type 2 diabetes in Europe and the United States, may reduce the number of ...

Novo Nordisk has launched its obesity therapy Saxenda in the US – its first market – with premium pricing compared to other drugs on the market. Saxenda (liraglutide) is a high-dose version of Novo ...

Novo Nordisk's (NVO) Saxenda (liraglutide 3 mg) received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for the treatment of obesity. The company intends to launch Saxenda ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Reduced body weight and improved ...